

**DROSPIRENONE 3mg / ESTETROL 14.2mg tablets (Drovelis® ▼) for contraception**

**The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of DROSPIRENONE 3mg / ESTETROL 14.2mg tablets (Drovelis® ▼) for contraception.**

**GREY**

Drospirenone 3mg / estetrol 14.2mg (Drovelis®) is licensed for oral contraception.<sup>[1]</sup>

This recommendation will be reviewed if a formal application for use is received and prioritised for in-year review.

In the meantime, treatment choices for contraception should continue to follow national guidance and local formulary choices:

- > The Faculty of Sexual and Reproductive Healthcare [Combined Hormonal Contraception](#), updated November 2020.
- > NICE Clinical Knowledge Summaries [Contraception - assessment](#), updated September 2022.
- > Pan Mersey APC Formulary: [Chapter 07.03.01 Combined hormonal contraceptives](#)

**References**

1. Gedeon Richter (UK) Ltd. Summary of product characteristics; [Drovelis 3 mg/14.2 mg film-coated tablets](#), 25 July 2022. Accessed 23 November 2022.

**Note:** Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.